Superior Precision, Dual Tumor Targeting with Reduced Systemic Toxicity

By employing dual-targeting of two independent cell surface antigens or epitopes, our molecules are designed to target either the disease cells themselves or the surrounding immune or stromal cells with great precision and reduced systemic toxicity.

Additionally, by selectively accumulating drug molecules in the disease environment rather than being distributed throughout the body, Elstar’s drugs have the potential of being effective at significantly lower doses and with reduced toxicities when compared with current therapies.